How much cash does Alto Neuroscience generate?

Alto Neuroscience (ANRO) generated -$62.3M in operating cash flow over the trailing twelve months.

What is Alto Neuroscience's free cash flow?

After $2.1M of capital expenditures, Alto Neuroscience's free cash flow was -$62.9M over the trailing twelve months, down 14.6% year over year.

Where does Alto Neuroscience's cash flow data come from?

Every line is extracted from Alto Neuroscience's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Alto Neuroscience ANRO Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$74.31M-17.5%	-$63.24M-1.6%	-$62.26M+4.0%	-$64.86M-2.7%	-$63.18M-2.9%
Depreciation and amortization	$641K+2.1%	$628K-2.0%	$641K0.0%	$641K0.0%	$641K+13.1%
Stock-based compensation	$8.96M+10.6%	$8.11M+4.9%	$7.73M+2.5%	$7.54M+1.6%	$7.42M-2.8%
Gain (loss) on sale of assets	-$124K+20.5%	-$156K+16.1%	-$186K-145%	-$76K+18.3%	-$93K-78.8%
Change in accounts payable	——	——	——	——	——
Change in accrued liabilities	——	——	——	——	$900K-77.5%
Change in other assets	——	——	——	——	——
Non-cash operating lease expense	$784K+1.3%	$774K-1.8%	$788K+32.9%	$593K+30.3%	$455K+35.0%
Loss on extinguishment of debt	$0+100%	-$681K0.0%	-$681K0.0%	-$681K0.0%	-$681K—
Net cash from operating activities	-$62.3M-20.4%	-$51.77M+2.8%	-$53.27M+3.3%	-$55.08M-3.9%	-$53M-11.8%
Capital expenditures	——	——	——	——	$1.88M-9.6%
Net cash from investing activities	——	——	——	——	-$1.88M+9.6%
Repayments of debt	——	——	——	——	$10.21M—
Proceeds from issuance of common stock	$511K-27.3%	$703K+75.8%	$400K+27.4%	$314K-16.3%	$375K+101%
Taxes paid for net share settlement	——	——	——	——	——
Payment of debt issuance costs	——	——	——	——	$127K—
Net cash from financing activities	$165.89M+176%	$60.08M+504%	$9.94M-10.5%	$11.11M+5.8%	$10.49M-92.3%
Effect of exchange rate changes on cash	-$24K+20.0%	-$30K—	——	——	——
Net increase (decrease) in cash	$103.01M+1,148%	$8.26M—	——	——	——
Interest paid	$1.69M+1.9%	$1.66M+11.9%	$1.48M+16.8%	$1.27M+19.6%	$1.06M+6.3%
Depreciation	$674K+2.0%	$661K-1.9%	$674K0.0%	$674K—	——
Change in other, net	$402K+22.9%	$327K+35.1%	$242K+36.0%	$178K—	——
Accrued expenses and other liabilities	——	——	——	——	$900K-77.5%
Increase (Decrease) in Prepaid Expense and Other Assets	——	——	——	——	——
Non-cash interest expense related to term loan	$755K+3.6%	$729K+11.8%	$652K+16.6%	$559K+17.7%	$475K+20.9%
Operating lease right-of-use asset amortization	$784K+1.3%	$774K-1.8%	$788K+32.9%	$593K+30.3%	$455K+35.0%
Costs From Sale Of Common Stock and Pre-Funded Warrants In Private Placement	——	——	——	——	$0—
Payments Of Debt Issuance Costs	——	——	——	——	$127K—
Payments on Issuance Cost from Registration Statement	——	——	——	$556K+32.7%	$419K—
Proceeds from sale of common stock and pre-funded warrants in 2026 private placement	——	——	——	——	$0—
Accrued payables for capital expenditures	——	——	——	——	——
Proceeds From Long Term Lines Of Credit	——	——	——	——	——
Issuance of warrants	——	——	——	——	$524K—
Costs from sale of common stock and pre-funded warrants in 2026 private placement not yet paid	——	——	——	——	$0—
Deferred offering and share issue costs not yet paid	——	——	——	——	$144K+1,700%
Free cash flow	-$62.86M-21.4%	-$51.79M+3.7%	-$53.8M+5.0%	-$56.62M-3.2%	-$54.87M-10.9%
Free cash flow	-$62.86M-21.4%	-$51.79M+3.7%	-$53.8M+5.0%	-$56.62M-3.2%	-$54.87M-10.9%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Alto Neuroscience generate?: Alto Neuroscience (ANRO) generated -$62.3M in operating cash flow over the trailing twelve months.
What is Alto Neuroscience's free cash flow?: After $2.1M of capital expenditures, Alto Neuroscience's free cash flow was -$62.9M over the trailing twelve months, down 14.6% year over year.
Where does Alto Neuroscience's cash flow data come from?: Every line is extracted from Alto Neuroscience's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.